Success Stories: Indian Senior Scientist in Pharmaceutical Sciences with Massive Citation Count of 1,444, Gets EB1-A and NIW Approvals with Our Team’s Efficient Case Preparation Strategy Quickly
Client’s Testimonial:
“Thank you very much for the update on the approval. This is very exciting news. Thank you for helping me to reach this stage.”
On November 29th, 2021 and December 20th, 2021, we received another EB-1A (Alien of Extraordinary Ability) and EB-2 NIW (National Interest Waiver) approval for a Senior Scientist in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Senior Scientist
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: November 29th, 2021 (EB-1A) and December 20th, 2021 (NIW)
Processing Time: 13 days (EB-1A) (Premium Processing Requested) and 6 months, 25 days (NIW)
Case Summary:
A senior scientist in pharmaceutical sciences from India wanted our help filing his NIW (National Interest Waiver) and EB1-A (Alien of Extraordinary Ability) petitions. Initially, he came to us with his NIW request which we helped him file in the month of May in 2021, and later we also helped him file an EB1-A in November of the same year. With premium processing upgrade and our diligent team effort, we were able to get him the approvals in less than the expected time for both the applications.
While the NIW category of the EB2 visa application requires the petitioner to prove their worth to the nation resulting in a labor certification and permanent job waiver, the EB1-A category requires the applicant to prove their extraordinary value for the proposed area of endeavor. Both of these categories thus requires careful case preparation and this is exactly where NAILG comes in. Our team was able to put together his petition for both the applications. Some of the things which were common to both of these were as follows:
- A detailed explanation of his work in the area showing that he wanted to develop safe and effective drug delivery platforms including lipid-based nanoparticles, extracellular vesicles, oral biotherapeutics, and hydrogels through techniques such as microfluidics and high-performance liquid chromatography in order to facilitate improved targeting and dosage in pharmaceuticals for treating conditions such as rheumatoid arthritis, diabetes, and cancer.
- Details of his major funding from the National Cancer Institute (NCI) of the National Institutes of Health.
- Details of his publication history showing that his research has resulted in 8 peer-reviewed journal articles (3 first-authored and 2 co-first-authored), 1 first-authored book chapter, and 4 international patent applications.
- Evidence showing that these publications have been cited a massive total of 1,444 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of pharmaceutical sciences.
- Evidence of 15 peer reviews conducted for prestigious scientific journals in his area of expertise.
- Finally, 2 letters of recommendation each showing the worth of his research for the national and the world.